• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

抗乙型肝炎病毒的高级 siRNA 递呈：机制见解和最新进展。

Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates.

机构信息

Department of Precision Medicine, School of Medicine, Sungkyunkwan University, Suwon, Gyeonggi, 16419, Republic of Korea.

出版信息

J Nanobiotechnology. 2024 Nov 30;22(1):745. doi: 10.1186/s12951-024-03004-3.

DOI:10.1186/s12951-024-03004-3
PMID:39616384
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11608496/
Abstract

Hepatitis B virus (HBV) infection is a major health problem, causing thousands of deaths each year worldwide. Although current medications can often inhibit viral replication and reduce the risk of liver carcinoma, several obstacles still hinder their effectiveness. These include viral resistance, prolonged treatment duration, and low efficacy in clearing viral antigens. To address these challenges in current HBV treatment, numerous approaches have been developed with remarkable success. Among these strategies, small-interfering RNA (siRNA) stands out as one of the most promising therapies for hepatitis B. However, naked siRNAs are vulnerable to enzymatic digestion, easily eliminated by renal filtration, and unable to cross the cell membrane due to their large, anionic structure. Therefore, effective delivery systems are required to protect siRNAs and maintain their functionality. In this review, we have discussed the promises of siRNA therapy in treating HBV, milestones in their delivery systems, and products that have entered clinical trials. Finally, we have outlined the future perspectives of siRNA-based therapy for HBV treatment.

摘要

乙型肝炎病毒 (HBV) 感染是一个主要的健康问题，每年在全球范围内导致数千人死亡。尽管目前的药物通常可以抑制病毒复制并降低肝癌风险，但仍存在一些障碍会影响其疗效。这些障碍包括病毒耐药性、治疗持续时间长以及清除病毒抗原的效果不佳。为了解决当前 HBV 治疗中的这些挑战，已经开发了许多方法，并取得了显著的成功。在这些策略中，小干扰 RNA (siRNA) 作为治疗乙型肝炎最有前途的疗法之一脱颖而出。然而，裸露的 siRNA 容易被酶消化，容易被肾脏过滤消除，并且由于其大的阴离子结构而无法穿过细胞膜。因此，需要有效的递药系统来保护 siRNA 并保持其功能。在这篇综述中，我们讨论了 siRNA 治疗在治疗乙型肝炎方面的前景、其递药系统的里程碑以及已进入临床试验的产品。最后，我们概述了基于 siRNA 的乙型肝炎治疗的未来展望。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/8ffaefd4579c/12951_2024_3004_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/568ccec1a5f4/12951_2024_3004_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/cdca2c85b933/12951_2024_3004_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/03b7343b734b/12951_2024_3004_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/724cbf7c0406/12951_2024_3004_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/855465e1ad63/12951_2024_3004_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/4285b924cc7e/12951_2024_3004_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/1f74e36c3c8c/12951_2024_3004_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/55f4e001c3b6/12951_2024_3004_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/8ffaefd4579c/12951_2024_3004_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/568ccec1a5f4/12951_2024_3004_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/cdca2c85b933/12951_2024_3004_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/03b7343b734b/12951_2024_3004_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/724cbf7c0406/12951_2024_3004_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/855465e1ad63/12951_2024_3004_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/4285b924cc7e/12951_2024_3004_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/1f74e36c3c8c/12951_2024_3004_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/55f4e001c3b6/12951_2024_3004_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1d34/11608496/8ffaefd4579c/12951_2024_3004_Fig9_HTML.jpg

相似文献

1
Advanced siRNA delivery in combating hepatitis B virus: mechanistic insights and recent updates.抗乙型肝炎病毒的高级 siRNA 递呈：机制见解和最新进展。
J Nanobiotechnology. 2024 Nov 30;22(1):745. doi: 10.1186/s12951-024-03004-3.
2
RNAi for treating hepatitis B viral infection.用于治疗乙型肝炎病毒感染的RNA干扰技术。
Pharm Res. 2008 Jan;25(1):72-86. doi: 10.1007/s11095-007-9504-0. Epub 2007 Dec 12.
3
siRNA drug development against hepatitis B virus infection.针对乙型肝炎病毒感染的 siRNA 药物研发。
Expert Opin Biol Ther. 2018 Jun;18(6):609-617. doi: 10.1080/14712598.2018.1472231. Epub 2018 May 8.
4
Inhibition of hepatitis B virus replication in vivo by nucleoside analogues and siRNA.核苷类似物和小干扰RNA在体内对乙型肝炎病毒复制的抑制作用
Gastroenterology. 2003 Jul;125(1):9-18. doi: 10.1016/s0016-5085(03)00720-0.
5
EsiRNAs inhibit Hepatitis B virus replication in mice model more efficiently than synthesized siRNAs.在小鼠模型中，esiRNAs比合成的siRNAs更有效地抑制乙型肝炎病毒复制。
Virus Res. 2006 Jun;118(1-2):150-5. doi: 10.1016/j.virusres.2005.12.005. Epub 2006 Jan 19.
6
Effective inhibition of hepatitis B virus replication by small interfering RNAs expressed from human foamy virus vectors.人泡沫病毒载体表达的小干扰RNA对乙型肝炎病毒复制的有效抑制作用
Int J Mol Med. 2007 Apr;19(4):705-11.
7
5'-triphosphate-siRNA activates RIG-I-dependent type I interferon production and enhances inhibition of hepatitis B virus replication in HepG2.2.15 cells.5'-三磷酸化 siRNA 激活 RIG-I 依赖性 I 型干扰素产生，并增强其对 HepG2.2.15 细胞中乙型肝炎病毒复制的抑制作用。
Eur J Pharmacol. 2013 Dec 5;721(1-3):86-95. doi: 10.1016/j.ejphar.2013.09.050. Epub 2013 Oct 5.
8
Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?评价 RNA 干扰技术治疗乙型肝炎的疗效：前景如何？
Viruses. 2024 Oct 31;16(11):1710. doi: 10.3390/v16111710.
9
Combination of small interfering RNA and lamivudine on inhibition of human B virus replication in HepG2.2.15 cells.小干扰RNA与拉米夫定联合抑制人乙型肝炎病毒在HepG2.2.15细胞中的复制
World J Gastroenterol. 2007 Apr 28;13(16):2324-7. doi: 10.3748/wjg.v13.i16.2324.
10
Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs.化学修饰的小干扰RNA在体内具有强大且持久的抗乙肝病毒活性。
Nat Biotechnol. 2005 Aug;23(8):1002-7. doi: 10.1038/nbt1122. Epub 2005 Jul 24.

引用本文的文献

1
Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D.乙型、丙型和丁型肝炎的发病机制、预防及治疗进展
Virol J. 2025 Aug 11;22(1):274. doi: 10.1186/s12985-025-02907-3.
2
Antiviral nanomedicine: Advantages, mechanisms and advanced therapies.抗病毒纳米药物：优势、作用机制及先进疗法
Bioact Mater. 2025 Jun 5;52:92-122. doi: 10.1016/j.bioactmat.2025.05.030. eCollection 2025 Oct.

本文引用的文献

1
Lipid nanoparticle-encapsulated DOCK11-siRNA efficiently reduces hepatitis B virus cccDNA level in infected mice.脂质纳米颗粒包裹的DOCK11小干扰RNA可有效降低感染小鼠体内的乙肝病毒共价闭合环状DNA水平。
Mol Ther Methods Clin Dev. 2024 Jun 24;32(3):101289. doi: 10.1016/j.omtm.2024.101289. eCollection 2024 Sep 12.
2
WHO's 2024 guidelines to combat hepatitis B.世界卫生组织2024年抗击乙型肝炎指南。
Lancet Infect Dis. 2024 Jun;24(6):e360. doi: 10.1016/S1473-3099(24)00308-6.
3
Roles Played by DOCK11, a Guanine Nucleotide Exchange Factor, in HBV Entry and Persistence in Hepatocytes.
DOCK11 作为鸟嘌呤核苷酸交换因子在 HBV 进入和在肝细胞中持续存在中的作用。
Viruses. 2024 May 8;16(5):745. doi: 10.3390/v16050745.
4
Perspective on Emerging Therapies to Achieve Functional Cure of Chronic Hepatitis B.实现慢性乙型肝炎功能性治愈的新兴疗法展望
Curr Hepatol Rep. 2024 Jun;23(2):241-252. doi: 10.1007/s11901-024-00652-9. Epub 2024 Feb 10.
5
Therapeutic advances in HBV cure.乙肝治愈方面的治疗进展。
Clin Liver Dis (Hoboken). 2024 Apr 15;23(1):e0161. doi: 10.1097/CLD.0000000000000161. eCollection 2024 Jan-Jun.
6
RNAi-based drug design: considerations and future directions.基于 RNAi 的药物设计：考虑因素和未来方向。
Nat Rev Drug Discov. 2024 May;23(5):341-364. doi: 10.1038/s41573-024-00912-9. Epub 2024 Apr 3.
7
RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects.用于慢性乙型肝炎的RNA干扰疗法：进展、挑战与未来前景
Microorganisms. 2024 Mar 17;12(3):599. doi: 10.3390/microorganisms12030599.
8
RNA interference in the era of nucleic acid therapeutics.核酸治疗时代的RNA干扰
Nat Biotechnol. 2024 Mar;42(3):394-405. doi: 10.1038/s41587-023-02105-y. Epub 2024 Feb 26.
9
Structural basis of hepatitis B virus receptor binding.乙型肝炎病毒受体结合的结构基础。
Nat Struct Mol Biol. 2024 Mar;31(3):447-454. doi: 10.1038/s41594-023-01191-5. Epub 2024 Jan 17.
10
Gene-Editing and RNA Interference in Treating Hepatitis B: A Review.基因编辑和 RNA 干扰在乙型肝炎治疗中的应用：综述。
Viruses. 2023 Dec 8;15(12):2395. doi: 10.3390/v15122395.